Table 1.
Demographic and baseline clinical characteristics of participants with SSD receiving antipsychotic augmentation with citalo-pram or placebo (n = 198)
| Characteristic | Placebo (n = 94) mean ± SD | Citalopram (n = 104) mean ± SD | F (d.f.) | p |
|---|---|---|---|---|
| Age, years | 51.7±6.3 | 53.1±7.7 | 2.032 (1,192) | 0.156 |
| Age at onset of first psychotic episode, years | 27.3±10.3 | 28.4±10.7 | 0.484 (1,167) | 0.488 |
| Education level, years | 11.8±2.3 | 12.1±2.1 | 0.938 (1,194) | 0.334 |
| HDRS | 13.4±4.1 | 13.6±4.4 | 0.057 (1,194) | 0.812 |
| CDRS | 7.0±3.1 | 6.5±3.2 | 1.957 (1,194) | 0.163 |
| PANSS | ||||
| Positive | 16.43±4.60 | 15.26±6.41 | 2.492 (1,194) | 0.116 |
| Negative | 16.17±5.45 | 15.40±4.44 | 3.870 (1,193) | 0.510 |
| n (%) | n (%) | χ2 (d.f) | p | |
| Female gender | 20 (21.3) | 23 (22.1) | 0.0149 (1) | 0.903 |
| Race | 3.029 (3) | 0.387 | ||
| White | 54 (57.4) | 54 (51.9) | ||
| Black | 26 (27.7) | 40 (38.5) | ||
| Hispanic | 9 (9.6) | 5 (4.8) | ||
| Other | 5 (5.3) | 5 (4.8) | ||
| Marital status | 15.169 (3) | 0.002 | ||
| Never (single) | 48 (32) | 32 (30.8) | ||
| Married or cohabitating | 10 (18) | 18 (17.3) | ||
| Divorced or separated | 35 (41) | 41 (39.4) | ||
| Widowed | 1 (13) | 13 (12.5) | ||
| Age <18 years at onset of first psychotic episode | 12 (9) | 9 (10.1) | 0.409 (1) | 0.522 |
| Ever attempted suicide | 41 (48) | 48 (47.5) | 1.891 (2) | 0.389 |
| Diagnosed schizoaffective | 33 (35.1) | 48 (46.2) | 1.521 (1) | 0.218 |
| Medications | 0.036 (2) | 0.982 | ||
| First-generation antipsychotics | 9 (9.9) | 10 (10.2) | ||
| Second-generation antipsychotics | 65 (71.4) | 69 (70.4) | ||
| Both first- and second-generation antipsychotics | 17 (18.7) | 19 (19.4) | ||
| Anticholinergics/antihistamines | 26 (28.6) | 30 (30.6) | 0.035 (1) | 0.853 |
| Antidepressant tapered off from ≥4 weeks prior to study | 15 (16.0) | 19 (18.3) | 0.386 (1) | 0.534 |